GUANGDONG LIFESTRONG PHARMACY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.77 CNY | -0.65% |
|
-5.47% | -31.72% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 7,720 | 3,139 | 3,930 |
| Enterprise Value (EV) 1 | 7,167 | 2,688 | 3,740 |
| P/E ratio | 101 x | 93.4 x | 117 x |
| Yield | 0.33% | 0.51% | - |
| Capitalization / Revenue | 22.1 x | 11.1 x | 13.4 x |
| EV / Revenue | 20.5 x | 9.49 x | 12.8 x |
| EV / EBITDA | 96.2 x | 82.5 x | 94 x |
| EV / FCF | 118 x | 49.5 x | -19.2 x |
| FCF Yield | 0.85% | 2.02% | -5.2% |
| Price to Book | 10.3 x | 4.14 x | 4.88 x |
| Nbr of stocks (in thousands) | 160,000 | 160,000 | 160,000 |
| Reference price 2 | 48.25 | 19.62 | 24.56 |
| Announcement Date | 4/24/22 | 4/27/23 | 4/21/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 290.5 | 316.6 | 341 | 349.8 | 283.3 | 292.4 |
| EBITDA 1 | 81.37 | 82.9 | 75.72 | 74.47 | 32.57 | 39.79 |
| EBIT 1 | 73.32 | 74.11 | 64.33 | 60.51 | 21.45 | 29.04 |
| Operating Margin | 25.24% | 23.41% | 18.87% | 17.3% | 7.57% | 9.93% |
| Earnings before Tax (EBT) 1 | 74.38 | 80.18 | 72.46 | 66.72 | 34.75 | 37.29 |
| Net income 1 | 63.6 | 66.63 | 62.52 | 57.18 | 33.42 | 33.5 |
| Net margin | 21.89% | 21.05% | 18.34% | 16.35% | 11.79% | 11.46% |
| EPS 2 | 0.5300 | 0.5600 | 0.5200 | 0.4800 | 0.2100 | 0.2100 |
| Free Cash Flow 1 | 31.02 | 11.58 | 8.476 | 60.76 | 54.26 | -194.5 |
| FCF margin | 10.68% | 3.66% | 2.49% | 17.37% | 19.15% | -66.51% |
| FCF Conversion (EBITDA) | 38.12% | 13.97% | 11.19% | 81.59% | 166.61% | - |
| FCF Conversion (Net income) | 48.77% | 17.39% | 13.56% | 106.26% | 162.38% | - |
| Dividend per Share | - | - | - | 0.1600 | 0.1000 | - |
| Announcement Date | 12/29/20 | 12/29/20 | 4/24/22 | 4/24/22 | 4/27/23 | 4/21/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 94 | 102 | 134 | 553 | 451 | 190 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 31 | 11.6 | 8.48 | 60.8 | 54.3 | -194 |
| ROE (net income / shareholders' equity) | 32.1% | 26.6% | 21% | 10.6% | 4.43% | 4.23% |
| ROA (Net income/ Total Assets) | 15.8% | 14.9% | 11.3% | 6.25% | 1.59% | 2.12% |
| Assets 1 | 401.4 | 448 | 551.3 | 914.8 | 2,098 | 1,581 |
| Book Value Per Share 2 | 1.920 | 2.260 | 2.700 | 4.690 | 4.740 | 5.040 |
| Cash Flow per Share 2 | 0.7800 | 0.6200 | 0.9000 | 3.030 | 1.120 | 0.8500 |
| Capex 1 | 1.35 | 12.8 | 46.1 | 3.09 | 5.54 | 38.6 |
| Capex / Sales | 0.47% | 4.05% | 13.52% | 0.88% | 1.96% | 13.21% |
| Announcement Date | 12/29/20 | 12/29/20 | 4/24/22 | 4/24/22 | 4/27/23 | 4/21/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -31.72% | 372M | |
| +32.36% | 694B | |
| +29.57% | 593B | |
| -1.60% | 371B | |
| +20.07% | 331B | |
| +6.04% | 290B | |
| +14.62% | 239B | |
| +10.20% | 209B | |
| -3.27% | 209B | |
| +9.27% | 169B |
- Stock Market
- Equities
- 301111 Stock
- Financials Guangdong Lifestrong Pharmacy Co., Ltd.
